Barry S. Skikne

has served as Chief Medical Officer since 2017, board member since 2011, and scientific advisor since the company's inception. Dr. Skikne is a Professor of Internal Medicine at the University of Kansas Medical Center in Hematology/Oncology. Prior to re-joining KUMC in 2016, Dr. Skikne served as the Executive Director of Clinical Research at Celgene Pharmaceuticals from 2008 to 2016. At Celgene, Dr. Skikne oversaw several large international Phase III clinical trials. Dr. Skikne is the author of more than ninety journal articles and book chapters. He has a B.S. (M.B.B.Ch.,) from the University of Witwatersrand, Johannesburg, SA, and an M.D. and a residency in Hematology and Oncology from the College of Physicians of South Africa.